Company data
SELLAS Life Sciences Group, Inc. employees and revenue per employee
SLS · Biotechnology · $2.78B market cap
SELLAS Life Sciences Group, Inc. had 17 employees at the end of fiscal Dec 2022, up 54.5% from a year earlier. Revenue for the year was $1.0M, down 86.8% from a year earlier, or $59K per employee. Revenue fell while headcount grew.
The latest annual report we hold is more than two years old, so these numbers may be out of date.
Employees
17
+54.5% YoY
Revenue
$1.0M
-86.8% YoY
Revenue / employee
$59K
Peer median $455K
Rank in industry
98 of 111
Biotechnology
Headcount against revenue
Both lines start at 100 in the first year we hold, so you can see which one grew faster.
Hover a year for the numbers.
| Year ending | Employees | Revenue | Per employee | Staff YoY | Revenue YoY |
|---|---|---|---|---|---|
| Dec 2022 | 17 | $1.0M | $59K | +54.5% | -86.8% |
| Dec 2021 | 11 | $7.6M | $691K | +57.1% | +300.0% |
| Dec 2020 | 7 | $1.9M | $271K | — | — |
Open roles: we have not matched a verified job board for this company yet.
SELLAS Life Sciences Group, Inc. against similar companies
The closest industry peers by revenue, from Biotechnology.
| Company | Employees | Revenue | Revenue / employee | Shape |
|---|---|---|---|---|
| SLS SELLAS Life Sciences Group, Inc. | 17 | $1.0M | $59K | Hiring into decline |
| CGON CG Oncology Inc. | 142 | $4.0M | $28K | Efficient growth |
| STTK Shattuck Labs, Inc. | 40 | $1.0M | $25K | Contracting |
| DNTH Dianthus Therapeutics, Inc. | 92 | $2.0M | $22K | Hiring into decline |
| ABSI Absci Corporation | 140 | $2.8M | $20K | Contracting |
| INBX Inhibrx Biosciences Inc. | 109 | $1.3M | $12K | Leaner |
| NGNE Neurogene Inc. | 107 | $925,000 | $9K | — |
| CLDX Celldex Therapeutics, Inc. | 198 | $1.5M | $8K | Hiring into decline |
| ARTV Artiva Biotherapeutics, Inc. | 89 | $251,000 | $3K | — |
Questions about SELLAS Life Sciences Group, Inc.
- How many employees does SELLAS Life Sciences Group, Inc. have?
- SELLAS Life Sciences Group, Inc. reported 17 employees for the fiscal year ending Dec 2022, in the annual report it filed on March 16, 2023. That is up 54.5% from a year earlier.
- What is SELLAS Life Sciences Group, Inc.'s revenue per employee?
- SELLAS Life Sciences Group, Inc. brought in $1.0M of revenue in fiscal Dec 2022, which is $59K per employee. That ranks 98 of 111 companies we track in Biotechnology, where the median is $455K.
- Where do these numbers come from?
- Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.
Outpick research
This page is the filings. The research is a membership.
On the first and third Friday of each month Outpick publishes one stock pick with the full case for owning it, adds it to a live portfolio you can audit, and writes a note when a position closes. A new account gets 21 days of the whole membership with no card, and nothing is charged when it ends.
Free game
Think you can pick better than the S&P 500?
Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.
Enter the challengeMore data
Compare SLS with the rest of the market
See who earns the most per employee, who is hiring, and who is cutting, across every company we track.
Source: employee counts and revenue as stated in SELLAS Life Sciences Group, Inc.'s annual reports (Form 10-K), latest filed March 16, 2023. This is data, not a recommendation to buy or sell SLS.